Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | Route 206 And Province Line Road PRINCETON NJ 08543 |
Tel: | N/A |
Website: | https://www.bms.com |
IR: | See website |
Key People | ||
Giovanni Caforio Executive Chairman of the Board | Michelle Weese Executive Vice President - Corporate Affairs, Member of the Leadership Team | Christopher S. Boerner Chief Executive Officer, Chief Operating Officer, Director |
David V. Elkins Executive Vice President, Chief Financial Officer, Member of the Leadership Team | Greg Meyers Executive Vice President, Chief Digital and Technology Officer, Member of the Leadership Team | Sandra Leung Executive Vice President, General Counsel, Member of the Leadership Team |
Samit Hirawat Executive Vice President, Chief Medical Officer, Global Drug Development, Member of the Leadership Team | Adam Lenkowsky Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team | Elizabeth A. Mily Executive Vice President - Strategy and Business Development, Member of the Leadership Team | Karin Shanahan Executive Vice President, Global Product Development & Supply, Member of the Leadership Team |
Business Overview |
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib. |
Financial Overview |
For the fiscal year ended 31 December 2023, Bristol-Myers Squibb Co revenues decreased 2% to $45.01B. Net income increased 27% to $8.03B. Revenues reflect Prioritized Brands-Revlimid segment decrease of 39% to $6.1B, Prioritized Brands-Sprycel segment decrease of 11% to $1.93B, United States segment decrease of 1% to $31.56B, other segment decrease of 16% to $699M. |
Employees: | 34,100 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $135,174M as of Dec 31, 2023 |
Annual revenue (TTM): | $45,006M as of Dec 31, 2023 |
EBITDA (TTM): | $20,625M as of Dec 31, 2023 |
Net annual income (TTM): | $8,025M as of Dec 31, 2023 |
Free cash flow (TTM): | $7,907M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $27,492M as of Dec 31, 2023 |
Shares outstanding: | 2,022,193,411 as of Feb 6, 2024 |
Index Membership: | S&P 500 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |